<p><b>Notes:</b> Relative rate estimates obtained using Poisson Regression</p><p>Adjusted for age, gender, history of AIDS or TB, and time updated viral load (<400, 400–9999, 10000+)</p><p>Mortality Rates by Latest CD4 Count (cells/mm<sup>3</sup>) for Phidisa Participants: Mortality Cohort.</p
BACKGROUND: CD4 count at start of combination antiretroviral therapy (ART) is strongly associated wi...
<p>Mortality by CD4 cell count at baseline and ART use among HIV-infected subjects.</p
BACKGROUND: CD4 cell count and viral loads are used in clinical trials as surrogate endpoints for as...
<p><b>Notes:</b><sup>1</sup> Adjusted for age, gender, history of AIDS or TB, and time-updated viral...
<p><b>Notes:</b> Relative rate estimates obtained using Poisson Regression</p><p><sup>1</sup>Adjuste...
<p>The mortality cohort is made up of 7,114 HIV+ participants: 1,771 enrolled into Phidisa 2 (the cl...
<p>Mortality by Latest CD4+ Cell Count and ART status for Phidisa Participants.</p
a<p>adjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, prior...
<p>*Adjusted for baseline gender, CD4 count, clinical stage, viral load, and calendar period. **In o...
Background: Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretrovira...
OBJECTIVE: To determine the relationship between mortality risk and the CD4 cell response to antiret...
<div><p>Background</p><p>Short-term morbidity and mortality rates for HIV positive soldiers in the S...
Summary Background Whether people living with HIV who have not received antiretroviral therapy (ART)...
OBJECTIVE: We compiled the largest dataset of seroconverter cohorts to date from 25 countries across...
BACKGROUND:Short-term morbidity and mortality rates for HIV positive soldiers in the South African N...
BACKGROUND: CD4 count at start of combination antiretroviral therapy (ART) is strongly associated wi...
<p>Mortality by CD4 cell count at baseline and ART use among HIV-infected subjects.</p
BACKGROUND: CD4 cell count and viral loads are used in clinical trials as surrogate endpoints for as...
<p><b>Notes:</b><sup>1</sup> Adjusted for age, gender, history of AIDS or TB, and time-updated viral...
<p><b>Notes:</b> Relative rate estimates obtained using Poisson Regression</p><p><sup>1</sup>Adjuste...
<p>The mortality cohort is made up of 7,114 HIV+ participants: 1,771 enrolled into Phidisa 2 (the cl...
<p>Mortality by Latest CD4+ Cell Count and ART status for Phidisa Participants.</p
a<p>adjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, prior...
<p>*Adjusted for baseline gender, CD4 count, clinical stage, viral load, and calendar period. **In o...
Background: Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretrovira...
OBJECTIVE: To determine the relationship between mortality risk and the CD4 cell response to antiret...
<div><p>Background</p><p>Short-term morbidity and mortality rates for HIV positive soldiers in the S...
Summary Background Whether people living with HIV who have not received antiretroviral therapy (ART)...
OBJECTIVE: We compiled the largest dataset of seroconverter cohorts to date from 25 countries across...
BACKGROUND:Short-term morbidity and mortality rates for HIV positive soldiers in the South African N...
BACKGROUND: CD4 count at start of combination antiretroviral therapy (ART) is strongly associated wi...
<p>Mortality by CD4 cell count at baseline and ART use among HIV-infected subjects.</p
BACKGROUND: CD4 cell count and viral loads are used in clinical trials as surrogate endpoints for as...